Organ preservation involves removal of organs from the bodies, which are then stored for transplantation. Organ preservation systems are exclusively prepared and maintained according to the biological environment (temperature and oxygen) needed to store particular organs. Different body organs require specific and suitable storage conditions to maintain their anatomical and physiological processes. Important parameters in organ preservation include delivering of high quality organs to the donors, matching the patient and organ suitability, and restart of life of the organs and sustaining functions after the transplantation. Organ transplantation process starts with removing the needed organ from the donor body, then the organ is stored and transported.
Major factors hampering the growth of the organ preservation solutions market during the forecast period constitutes of advent of stem cells, and high costs.
- This report provides in-depth analysis of the global organ preservation solutions market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2026 - 2033), considering 2025, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global organ preservation solutions market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Dr. Franz Köhler Chemie GmbH, BioLife Solutions, XVIVO Perfusion AB, Bristol-Myers Squibb, Inc., and ToleroTech, Inc., Lifeline Scientific, Preservation Solutions Inc., Claris Injectables Limited, 21st Century Medicine, Paragonix Technologies Inc., BioTime, Inc. CryoLife, Inc., and Dr. Franz Köhler Chemie GmbH.
- Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The global organ preservation solutions market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
-
- Viaspan
- Custodiol HTK
- Renograf
- Hypothermosol
- Perfadex
- Lifor
- HBS Solution
- siRNA Transplant Solutions
- Others
-
- Hypothermic Perfusion Preservation
- Static Cold Storage
- Others
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Teva Pharmaceutical Industries Ltd.
- Franz Köhler Chemie GmbH
- BioLife Solutions
- XVIVO Perfusion AB
- Bristol-Myers Squibb, Inc.
- ToleroTech, Inc.
- Lifeline Scientific
- Preservation Solutions Inc.
- Claris Injectables Limited
- 21st Century Medicine
- Paragonix Technologies Inc.
- BioTime, Inc.
- CryoLife, Inc.
